Texas Woman Is the First Person to Undergo Optogenetic Therapy
By Katherine Bourzac,
MIT Technology Review
| 03. 18. 2016
Untitled Document
A blind woman in Texas is the first person to undergo therapy based on an emerging technology called optogenetics. If successful, the therapy will create light-sensing cells in one of her eyes and enable her to see again.
This patient and others being recruited for a clinical trial have a degenerative disease called retinitis pigmentosa. In this disease, the light-sensitive cells of the retina gradually die off. These cells pass electrical signals on to nerves that convey them to the brain.
The therapy uses optogenetics, a technology that uses a combination of gene therapy and light to precisely control nerves. The therapy should make certain nerve cells in the woman’s eye, called ganglion cells, light-sensitive. The eye was injected with viruses carrying DNA from light-sensitive algae. If it works, the cells will do what the healthy retina’s cones and rods do: fire off an electrical signal in response to light, restoring some vision.
Read more...
Image via Wikimedia
Related Articles
By [cites CGS' Katie Hasson], KCBS Radio | 11.19.2025
This is Ask An Expert, where every weekday at 9:20am, KCBS Radio is giving you direct access to top experts in various fields. Today: Gene-editing technology allows scientists to work with DNA in unprecedented ways, but there are larger scientific...
By Alice Miranda Ollstein and Megan Messerly, Politico | 10.25.2025
By Ben Foldy, The Wall Street Journal | 10.21.2025
AnnaMaria Gallozzi and her husband wanted to have a second child last year. Because Gallozzi has advanced breast cancer, the couple sought out a surrogate who could carry their baby.
They used crowdfunding and took out a second mortgage on...
By Megan Molteni and Anil Oza, STAT | 10.07.2025
For two years, a panel of scientific experts, clinicians, and patient advocates had been hammering out ways to increase community engagement in National Institutes of Health-funded science. When they presented their road map to the NIH Director Jay Bhattacharya last...